The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.

Ferrandina, M. G., Corrado, G., Mascilini, F., Malaguti, P., Samaritani, R., Distefano, M. G., Masciullo, V., Di Legge, A., Savarese, A., Scambia, G., Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study, <<BMC CANCER>>, 2014; 14 (Dicembre): 947-947. [doi:10.1186/1471-2407-14-947] [http://hdl.handle.net/10807/67109]

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

Ferrandina, Maria Gabriella;Corrado, Giacomo;Mascilini, Floriana;Malaguti, Paola;Distefano, Maria Grazia;Masciullo, Valeria;Scambia, Giovanni
2014

Abstract

The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.
2014
Inglese
Ferrandina, M. G., Corrado, G., Mascilini, F., Malaguti, P., Samaritani, R., Distefano, M. G., Masciullo, V., Di Legge, A., Savarese, A., Scambia, G., Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study, <<BMC CANCER>>, 2014; 14 (Dicembre): 947-947. [doi:10.1186/1471-2407-14-947] [http://hdl.handle.net/10807/67109]
File in questo prodotto:
File Dimensione Formato  
2. MOC.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 324.91 kB
Formato Adobe PDF
324.91 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/67109
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 22
social impact